{"url_path":"/sec/avtx/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000032-index.html","accession_number":"0001534120-26-000032","cik":"0001534120","ticker":"AVTX","issuer_name":"Avalo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000032-index.html","primary_entity_key":"0001534120","primary_entity_name":"Avalo Therapeutics, Inc."},"word_count":75,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits.\n\n(d)    Exhibits:\n\nExhibit No. Description\n\n99.1\n[Press release, dated Ma](ex-9911q2026earningsrelease.htm)[y](ex-9911q2026earningsrelease.htm)[13](ex-9911q2026earningsrelease.htm)[, 2026.](ex-9911q2026earningsrelease.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\n1\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nAVALO THERAPEUTICS, INC.\n\nDate: May 13, 2026By:/s/ Christopher Sullivan\n\nChristopher Sullivan\n\nChief Financial Officer\n\n2"}